CDKN2A and melanoma: We further validated our findings in another immunotherapy-resistant tumor model, YUMM1.7, a mouse melanoma line containing human-relevant mutations (BrafV600E; Cdkn2a−/− Pten−/−; Tyrosinase:CreERT2).